Program
Immunoglobulins
Also written as “IgPro10”, “TAK-771” and “Immunoglobulins Intravenous (Human)”.
Its studies are mostly in Primary Immunodeficiency Diseases · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Agammaglobulinemia · Scleroderma, Diffuse · Purpura, Thrombocytopenic, Idiopathic, led by 4 companies.
Drug pageImmunoglobulins: every studyAll 47 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSLits history only | 111 open or running | phase 4since Jul 7, 2011 | Sep 12, 2005 | Dec 20, 2029phase 4 · NCT03684018 |
| Takedaits history only | 60 open or running | phase 3since Sep 11, 2015 | Sep 11, 2015 | none ahead |
| GC Biopharma | 10 open or running | phase 3since Feb 19, 2018 | Feb 19, 2018 | none ahead |
| Kedrionits history only | 11 open or running | phase 3since Dec 16, 2024 | Dec 16, 2024 | Dec 20, 2027phase 3 · NCT06752356 |
Also a collaborator on its studies: Takeda Development Center Americas.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of GC Biopharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 19, 2018First study: phase 3 study in Primary Immunodeficiency DiseasesFirst studyNCT03492710
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study GC Biopharma leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03492710Primary Immunodeficiency Diseases | 3 | Withdrawn | Apr 30, 2019 | 0 |
How it is read
Names in the registry
- “IgPro10”, 4 entries
- “TAK-771”, 3 entries
- “Immunoglobulins Intravenous (Human)”, 3 entries
- “Immunoglobulin”, 2 entries
- “Immune globulin (human) 10% solution for intravenous administration”, 1 entry
Codes read as this program: IGPRO10.
Conditions, from the studies’ own filings
- Primary Immunodeficiency Diseases, 8 studies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 4 studies
- Agammaglobulinemia, 3 studies
- Scleroderma, Diffuse, 2 studies
- Purpura, Thrombocytopenic, Idiopathic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.